Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFRm NSCLC?  


Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution